Citigroup
FPRX

Citigroup’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Citigroup’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-10,000
Closed -$219K – 7744
2017
Q4 		$219K Buy
+10,000
New +$322K ﹤0.01% 4968

Citigroup's FPRX Position: Q2 2021 in Review

Citigroup sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 110,134 shares — an estimated $4.15M sold.

Citigroup first reported a position in FPRX in Q4 2013 and held it in 30 quarters. The position peaked at $5.14M in Q4 2016. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.

  • Citigroup reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
  • Citigroup sold 110,134 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $4.15M.
  • Citigroup first reported a position in Five Prime Therapeutics, Inc. in Q4 2013 and held it in 30 quarters.
  • Citigroup's Five Prime Therapeutics, Inc. position peaked at $5.14M in Q4 2016.
  • 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.

Based on Citigroup's 13F filing for Q2 2021, filed 10 Aug 2021.